Q32 Bio INC 10-Q quarterly reports

Q32 Bio Inc. reported progress in its bempikibart program for alopecia areata, alongside significant capital raises and a reduction in operating expenses.

Q32 Bio Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing a net loss of $7.6 million and strategic updates including the sale of ADX-097 assets and continued development of bempikibart.

Q32 Bio Inc. reported reduced net losses and extended its cash runway into 2027, while resolving a Nasdaq listing compliance issue and advancing its lead drug, bempikibart, with Fast Track designation.

Q32 Bio Inc. reported a net loss of $9.5 million for Q2 2025, narrowing its strategic focus to bempikibart for alopecia areata and discontinuing the ADX-097 program.

Q32 Bio Inc. reports a net loss of $11.0 million for Q1 2025, focusing on the advancement of bempikibart and evaluating strategic options for its complement inhibitor platform.

Q32 Bio Inc. reports a net loss of $17.6 million for the third quarter of 2024, alongside updates on clinical trials and financial activities.

Q32 Bio Inc. reports its second quarter 2024 financial results, highlighting a net loss of $15.9 million and progress in clinical trials for its lead product candidates.

Q32 Bio reports its first quarter 2024 results, highlighting a net income of $1 million driven by a gain on convertible notes, following its merger with Homology Medicines.